Clinical Trials Logo

Advanced Solid Cancers clinical trials

View clinical trials related to Advanced Solid Cancers.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03254732 Terminated - Clinical trials for Advanced Solid Cancers

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Start date: July 14, 2017
Phase: Phase 1
Study type: Interventional

This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks. Assessment of safety and tolerability of drug combination

NCT ID: NCT00886782 Terminated - Metastatic Cancer Clinical Trials

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Start date: May 31, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.

NCT ID: NCT00337376 Terminated - Clinical trials for Advanced Solid Cancers

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Start date: February 2006
Phase: Phase 1
Study type: Interventional

Rapamycin is a drug that has been approved by the Food and Drug Administration (government) for use in patients receiving a kidney transplant to prevent the patient's body from rejecting the transplanted kidney. It has shown antitumor effects in the laboratory, but has not been approved at this time for the treatment of cancer. Abraxane is a new form of chemotherapy that has been approved by the Food and Drug Administration for the treatment of metastatic breast cancer, and is a promising drug that is being evaluated in clinical trials for treatment of other cancers. This is a phase I study designed to find out if different doses of Rapamycin, when combined with Abraxane, are safe and well tolerated.